Arrhythmia Clinical Trial
— ICARIOSOfficial title:
Double Blind Placebo Controlled Dose Ranging Study of the Efficacy and Safety of SSR149744C 100 OR 300 mg for the Prevention of Ventricular Arrhythmia-Triggered ICD Interventions
Primary objective:
- to assess the efficacy of SSR149744C for the prevention of ventricular
arrhythmia-triggered ICD interventions.
Secondary objectives:
- to assess versus placebo the tolerability of the different dose regimens of SSR149744C
in the selected population.
- to document SSR149744C plasma level during the study.
Status | Completed |
Enrollment | 153 |
Est. completion date | February 2007 |
Est. primary completion date | February 2007 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 21 Years and older |
Eligibility |
Inclusion Criteria: - Patient with an ICD implanted during the previous year for documented spontaneous life-threatening ventricular arrhythmia OR implanted with an ICD and with at least one appropriate ICD therapy (shock or anti-tachycardia pacing) for ventricular tachycardia or ventricular fibrillation in the previous year. - Left ventricular ejection fraction measured by 2D-echocardiography must have been documented to be less than 40% in the last 6 months. Exclusion Criteria: MAIN CRITERIA (non-exhaustive list): - Women of childbearing potential without adequate birthcontrol, Pregnant Women, Breastfeeding women, conditions which increase the risk of severe antiarrhythmic drug side effects, severe associated conditions. |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Belgium | Sanofi-Aventis Administrative Office | Diegem | |
Canada | Sanofi-Aventis Administrative Office | Laval | |
Czech Republic | Sanofi-Aventis Administrative Office | Praha | |
Germany | Sanofi-Aventis Administrative Office | Berlin | |
Italy | Sanofi-Aventis Administrative Office | Milano | |
Netherlands | Sanofi-Aventis Administrative Office | Gouda | |
Switzerland | Sanofi-Aventis Administrative Office | Geneva | |
United States | Sanofi-Aventis Administrative Office | Bridgewater | New Jersey |
Lead Sponsor | Collaborator |
---|---|
Sanofi |
United States, Belgium, Canada, Czech Republic, Germany, Italy, Netherlands, Switzerland,
Gojkovic O, Aliot EM, Capucci A, Connolly SJ, Crijns H, Hohnloser SH, Kulakowski P, Roy D, Radzik D, Singh BN, Kowey PR. Celivarone in patients with an implantable cardioverter-defibrillator: adjunctive therapy for the reduction of ventricular arrhythmia- — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Primary endpoint is time to all ventricular tachycardia or ventricular fibrillation arrhythmia leading to any ICD intervention (anti-tachycardia pacing or ICD shock). | |||
Secondary | Time to all arrhythmia episodes leading to at least one documented ICD shock. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05048602 -
Drug-induced Brugada Syndrome Research Database
|
||
Completed |
NCT05053243 -
Clinical Validation of the AliveCor Kardia 12L and 6L Devices
|
N/A | |
Completed |
NCT01913561 -
The Use of Master Caution Garment for Continuous Monitoring for Arrhythmia Detection
|
N/A | |
Completed |
NCT01688648 -
Comparison Between Lidocaine, Dexmedetomidine, and Their Combined Infusion in Subjects Undergoing Coronary Artery Bypass Graft
|
N/A | |
Completed |
NCT01396226 -
A Multi-centre Study Comparing the Effects of AZD2927 and Placebo on the Electrical Activity in the Heart in Patients
|
Phase 2 | |
Terminated |
NCT00624520 -
Mental Stress Reduction in Defibrillator Patients
|
Phase 3 | |
Completed |
NCT00756886 -
Does Atorvastatin Prevent Post Operative Atrial Fibrillation After Pulmonary Resection: A Randomized Clinical Study
|
N/A | |
Terminated |
NCT00721149 -
NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Symptomatic Paroxysmal Atrial Fibrillation- Treatment Use Study
|
Phase 3 | |
Completed |
NCT00510029 -
Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of GAP-134 Administered Intravenously
|
Phase 1 | |
Completed |
NCT00578617 -
Ablation vs Drug Therapy for Atrial Fibrillation - Pilot Trial
|
N/A | |
Active, not recruiting |
NCT00135174 -
Cost-Effectiveness of Routine Follow-up Visits in Patients With a Pacemaker: The Followpace Study
|
N/A | |
Completed |
NCT00119847 -
Electrophysiological Effects of Late PCI After MI
|
N/A | |
Completed |
NCT00035490 -
Efficacy and Safety Evaluation of Azimilide Dihydrochloride in Patients With Implantable Cardioverter Defibrillators
|
Phase 3 | |
Completed |
NCT00023556 -
Genetic Architecture of Heart Disease in Rural Brazil
|
N/A | |
Completed |
NCT00004560 -
Public Access Defibrillation (PAD) Community Trial
|
Phase 3 | |
Completed |
NCT01076361 -
Model 4968 CAPTURE EPI® STERIOD-ELUTING BIPOLAR EPICARDIAL PACING LEAD Post-approval Study
|
N/A | |
Recruiting |
NCT00138931 -
Genetics of Cardiovascular and Neuromuscular Disease
|
||
Completed |
NCT00622453 -
Arrhythmias in Myotonic Muscular Dystrophy
|
N/A | |
Completed |
NCT01076348 -
Model 4965 Post-Approval Study
|
||
Completed |
NCT00000531 -
Antiarrhythmics Versus Implantable Defibrillators (AVID)
|
Phase 3 |